52Q0 Stock Chart & Stats
€0.04
€0.00(0.00%)
At close: 4:00 PM EST
€0.04
€0.00(0.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €1.55
Previous CloseN/A
VolumeN/A
Average Volume (3M)27.40K
Market Cap
€6.19M
Enterprise Value€380.03M
Total Cash (Recent Filing)€19.51M
Total Debt (Recent Filing)€240.41M
Price to Earnings (P/E)―
Beta8.48
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding1,736,062,300
10 Day Avg. Volume65,941
30 Day Avg. Volume27,397
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00073
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthThe sharp TTM revenue increase indicates improving commercial traction and expanding business scale. If growth persists, it can provide operating leverage, broaden the company’s customer and product base, and create a foundation for eventual profitability as investment becomes more productive.
Improved Operating Cash FlowThe move to positive operating cash flow is a constructive sign that the underlying business is beginning to convert activity into cash. Sustained improvement would reduce reliance on external funding, support execution of the commercial plan, and strengthen financial resilience over the next several quarters.
Positive Equity And Moderate LeveragePositive equity and moderate TTM leverage provide a more stable capital base than an overleveraged structure would. This supports continued operations and investment while giving management some financial flexibility, although the benefit depends on improving losses and preventing further balance-sheet deterioration.
Bears Say
Severe And Worsening LossesVery large operating and net losses show that revenue growth is not yet translating into an economically sustainable business. The widening net loss suggests costs are rising faster than sales, which may require prolonged restructuring or investment before the company can build durable earnings power.
Negative Free Cash FlowNegative free cash flow means the company is still not generating enough cash after its operating and investment requirements. If this persists, continued funding needs could constrain product development and commercialization, while increasing dependence on financing during a period of substantial losses.
Rising Debt And Financial InstabilityThe substantial increase in debt raises financial risk while the company remains unprofitable and cash flow is not yet consistently positive. Historical negative equity and balance-sheet volatility further indicate that future losses could erode capitalization and limit strategic flexibility.
52Q0 FAQ
What was AegirBio AB’s price range in the past 12 months?
AegirBio AB lowest stock price was <€0.01 and its highest was €1.55 in the past 12 months.
What is AegirBio AB’s market cap?
AegirBio AB’s market cap is €6.19M.
When is AegirBio AB’s upcoming earnings report date?
AegirBio AB’s upcoming earnings report date is Nov 05, 2026 which is in 11 days.
How were AegirBio AB’s earnings last quarter?
AegirBio AB released its earnings results on Aug 20, 2026. The company reported -€0.001 earnings per share for the quarter.
Is AegirBio AB overvalued?
According to Wall Street analysts AegirBio AB’s price is currently Overvalued.
Does AegirBio AB pay dividends?
AegirBio AB does not currently pay dividends.
What is AegirBio AB’s EPS estimate?
AegirBio AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AegirBio AB have?
AegirBio AB has 1,736,062,300 shares outstanding.
What happened to AegirBio AB’s price movement after its last earnings report?
AegirBio AB reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of AegirBio AB?
Currently, no hedge funds are holding shares in DE:52Q0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AegirBio AB
Subgen AI AB develops artificial intelligence-based models and applications to control data for government and businesses. The company engages in the provision of information society services aimed at delivering financial and related knowledge tools to facilitate third-party access to financial literacy and instruments that enable them to interpret such information through e-learning; the acquisition, ownership, management and administration of securities; and the acquisition, ownership, marketing, leasing and operation of rural or urban properties. It also provides financial intermediation services; computer programming activities, structure and content design, writes computer code for systems, computer software, databases and web pages; and customizes computer programs, including configuration and modification of legacy programs. In addition, the company offers marketing and after-sales services of diagnostic imaging machinery and human resources services, as well as development of state-of-the-art artificial intelligence (Al) systems. Further, it provides Serenity Star, AI4D core, and Substrate Cloud. The company is based in London, United Kingdom. Subgen AI AB operates as a subsidiary of Substrate Artificial Inteligence, S.A.